Correction: Cost‑effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands.
作者信息
Quist Sara W, van Schoonhoven Alexander V, Bakker Stephan J L, Pochopień Michał, Postma Maarten J, van Loon Jeanni M T, Paulissen Jeroen H J
机构信息
Department of Health Sciences, University of Groningen, Groningen, The Netherlands.
Asc Academics, Groningen, The Netherlands.
出版信息
Cardiovasc Diabetol. 2025 May 15;24(1):212. doi: 10.1186/s12933-025-02752-2.
Abstract
摘要
相似文献
1
Correction: Cost‑effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands.更正：非奈利酮在荷兰2型糖尿病相关慢性肾脏病中的成本效益。
Cardiovasc Diabetol. 2025 May 15;24(1):212. doi: 10.1186/s12933-025-02752-2.
2
Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands.在荷兰，用于 2 型糖尿病相关慢性肾病的非奈利酮的成本效益分析。
Cardiovasc Diabetol. 2023 Nov 28;22(1):328. doi: 10.1186/s12933-023-02053-6.
3
Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.非奈利酮降低慢性肾脏病和 2 型糖尿病患者的心力衰竭事件风险：FIGARO-DKD 试验分析。
Circulation. 2022 Feb 8;145(6):437-447. doi: 10.1161/CIRCULATIONAHA.121.057983. Epub 2021 Nov 13.
4
Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis.在患有 2 型糖尿病和慢性肾病的患者中，使用非奈利酮与治疗后肺炎和 COVID-19 不良事件减少相关：FIDELITY 汇总二次分析。
JAMA Netw Open. 2022 Oct 3;5(10):e2236123. doi: 10.1001/jamanetworkopen.2022.36123.
5
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.在 2 型糖尿病合并慢性肾脏病患者中，用非奈利酮治疗的心血管和肾脏结局：FIDELITY 汇总分析。
Eur Heart J. 2022 Feb 10;43(6):474-484. doi: 10.1093/eurheartj/ehab777.
6
Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial.探讨 finerenone 在 1 型糖尿病合并慢性肾脏病患者中应用的一项随机 III 期注册临床试验的原理和设计：FINE-ONE 试验。
Diabetes Res Clin Pract. 2023 Oct;204:110908. doi: 10.1016/j.diabres.2023.110908. Epub 2023 Oct 5.
7
Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes.在 2 型糖尿病合并慢性肾脏病患者中用非奈利酮治疗血压和心肾结局。
Hypertension. 2022 Dec;79(12):2685-2695. doi: 10.1161/HYPERTENSIONAHA.122.19744. Epub 2022 Oct 12.
8
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.非奈利酮与慢性肾脏病合并 2 型糖尿病患者的心血管结局。
Circulation. 2021 Feb 9;143(6):540-552. doi: 10.1161/CIRCULATIONAHA.120.051898. Epub 2020 Nov 16.
9
Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.非奈利酮可降低慢性肾脏病合并 2 型糖尿病患者的新发心房颤动风险。
J Am Coll Cardiol. 2021 Jul 13;78(2):142-152. doi: 10.1016/j.jacc.2021.04.079. Epub 2021 May 17.
10
Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes.非奈利酮在慢性肾脏病和糖尿病患者中的肾脏功能/蛋白尿与心衰结局。
JACC Heart Fail. 2022 Nov;10(11):860-870. doi: 10.1016/j.jchf.2022.07.013. Epub 2022 Oct 12.
本文引用的文献
1
Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands.在荷兰，用于 2 型糖尿病相关慢性肾病的非奈利酮的成本效益分析。
Cardiovasc Diabetol. 2023 Nov 28;22(1):328. doi: 10.1186/s12933-023-02053-6.
Zotero 插件